Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734502 | 0.88 | KDM4E (0.57) | KDM4EADORA3L3MBTL1 | |
| SCHEMBL1734511 | 0.87 | KDM4E (0.66) | KDM4EADORA3ADORA1CDK9 | |
| SCHEMBL1733524 | 0.87 | KDM4E (0.56) | KDM4ESLC9A1L3MBTL1 | |
| SCHEMBL1734433 | 0.86 | KDM4E (0.60) | KDM4ESCN9AGRM2 | |
| SCHEMBL1733539 | 0.85 | KDM4E (0.54) | KDM4EADORA3ADORA1CTSAL3MBTL1 | |
| SCHEMBL1733601 | 0.84 | KDM4E (0.60) | KDM4ESCN9AGRM2 | |
| SCHEMBL1733602 | 0.81 | KDM4E (0.67) | KDM4EADORA3GRM2L3MBTL1 | |
| SCHEMBL1734279 | 0.81 | KDM4E (0.64) | KDM4EADORA3ADORA1SCN9AL3MBTL1 | |
| SCHEMBL1733534 | 0.81 | KDM4E (0.57) | KDM4EADORA3GRM2L3MBTL1 | |
| SCHEMBL1733468 | 0.81 | KDM4E (0.57) | KDM4EADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | claimed |
| EP-1891018-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131686-A1 | A THERMALLY CONTROLLED ASSEMBLY | NAPATECH A/S (DK) | 2011-10-27 | — | — | WO | claimed |
| EP-1891018-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | claimed |
| WO-2006127588-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | claimed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822451-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105833-A1 | Modulators of ATP-binding cassette transporters | ABCC4, CFTR, ABCC2 | KDM4E 3910/4885SLC9A1 154/4885ADORA3 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.